Valuation: Fortress Biotech, Inc.

Market Cap 92.38M 79.1M 73.8M 67.72M 127M 8.84B 130M 875M 341M 4.43B 347M 339M 14.67B P/E 2026 *
1.15x
P/E 2027 * -5.54x
Enterprise Value 92.38M 79.1M 73.8M 67.72M 127M 8.84B 130M 875M 341M 4.43B 347M 339M 14.67B EV / Sales 2026 *
1.16x
EV / Sales 2027 * 0.75x
Free-Float
77.3%
Yield 2026 *
-
Yield 2027 * -
1 day-2.81%
1 week-7.05%
Current month-11.50%
1 month-16.82%
3 months+4.53%
6 months-17.56%
Current year-24.32%
1 week 2.73
Extreme 2.7301
2.93
1 month 2.57
Extreme 2.57
3.65
Current year 2.18
Extreme 2.18
4.53
1 year 2.18
Extreme 2.18
4.53
3 years 1.24
Extreme 1.24
7.14
5 years 1.24
Extreme 1.24
57.15
10 years 1.24
Extreme 1.24
91.5
Manager TitleAgeSince
Chief Executive Officer 71 19/12/2013
Director of Finance/CFO 51 21/02/2012
Director of Finance/CFO 36 15/08/2022
Director TitleAgeSince
Director/Board Member 74 30/11/2008
Chairman 71 19/12/2013
Director/Board Member 63 31/05/2006
Date Insider Type Main position Quantity % Market Cap.
01/01/26 Free

Director

27,322 0.0880%
01/01/26 Free

Director

27,322 0.0880%
01/01/26 Free

Director

27,322 0.0880%
Change 5-day change 1-year change 3-year change Capi.($)
-2.81%-7.05%+35.12%-57.58% 92.38M
-1.69%+2.56%+39.87%+1.75% 82.54B
-23.55%+109.46%+395.80%+31.19% 53.23B
-1.69%+23.30%-25.53%-36.93% 58.38B
+1.94%+0.64%+0.46%+32.78% 52.24B
-0.23%+2.31%+9.15%+166.50% 48.52B
-3.25%+1.76%+54.22%-17.92% 31.67B
-0.97%+5.56%+47.59%+98.66% 25.79B
+1.19%+9.17%+3.12%+228.73% 22.46B
-0.43%+4.36%+60.70%+123.98% 16.91B
Average -0.39%+14.61%+62.05%+57.12% 39.18B
Weighted average by Cap. -0.10%+20.07%+69.88%+47.59%

Financials

2026 *2027 *
Net sales 79.88M 68.39M 63.81M 58.55M 110M 7.64B 112M 757M 295M 3.83B 300M 293M 12.68B 123M 105M 98.26M 90.16M 169M 11.77B 173M 1.17B 454M 5.9B 462M 452M 19.53B
Net income 90.51M 77.5M 72.31M 66.35M 125M 8.66B 127M 858M 334M 4.34B 340M 332M 14.37B -20.84M -17.84M -16.65M -15.27M -28.7M -1.99B -29.27M -197M -76.98M -999M -78.24M -76.54M -3.31B
Net Debt - -
Logo Fortress Biotech, Inc.
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Employees
78
Date Price Change Volume
20/08/26 US$2.770 -2.81% 323,758
19/08/26 US$2.850 -2.06% 536,559
18/08/26 US$2.910 +3.19% 593,190
17/08/26 US$2.820 -3.75% 838,776
14/08/26 US$2.930 -1.68% 1,031,522
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.770USD
Average target price
11.00USD
Spread / Average Target
+297.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBIO Stock